DOXYCYCLINE HYCLATE

Post-LOE

doxycycline hyclate

Charter Medical

ANDAORALTABLET, DELAYED RELEASE

Approved

Apr 2013

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DOXYCYCLINE HYCLATE (doxycycline hyclate) by Charter Medical is tetracycline-class antimicrobial drug [ see ]. Approved for rocky mountain spotted fever, typhus fever, the typhus group and 19 more indications. First approved in 2013.

Drug data last refreshed 18h ago

Mechanism of Action

tetracycline-class antimicrobial drug [ see ].

Indications (22)

Rocky Mountain spotted fever typhus fever the typhus group

Worked on DOXYCYCLINE HYCLATE at Charter Medical? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (2)

NCT01087476Phase 2Unknown

Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate

Started May 2010

164 enrolled

Mucositis

NCT00688064Phase 3Completed

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

Started Aug 2008

459 enrolled

Severe Acne Vulgaris